论文部分内容阅读
目的观察紫杉醇和卡铂静脉联合腹腔化疗治疗晚期卵巢癌的近期疗效及不良反应。方法 60例晚期卵巢上皮癌患者采用紫杉醇静脉化疗,其中紫杉醇135mg/m2,卡铂以曲线面积(AUC)=5腹腔给药,3周为1周期,至少完成2个疗程观察疗效。结果 60例患者中,完全缓解11例,部分缓解32例,进展17例,有效率为71.7%。Karnofsky评分,治疗前后存在统计学意义(P<0.01)。主要不良反应为骨髓抑制、恶心呕吐和脱发。结论紫杉醇和卡铂静脉联合腹腔化疗治疗晚期卵巢癌有较好疗效,不良反轻,耐受性好。
Objective To observe the short-term efficacy and side effects of paclitaxel and carboplatin combined with intraperitoneal chemotherapy in the treatment of advanced ovarian cancer. Methods Sixty patients with advanced epithelial ovarian cancer were treated with paclitaxel intravenous chemotherapy, including paclitaxel 135mg / m2 and carboplatin with a curve area (AUC) = 5 intraperitoneally, and 3 weeks for 1 cycle. At least 2 courses of chemotherapy were observed. Results In 60 patients, complete remission in 11 cases, partial remission in 32 cases, progress in 17 cases, the effective rate was 71.7%. Karnofsky score, before and after treatment was statistically significant (P <0.01). The main adverse reactions were myelosuppression, nausea, vomiting and hair loss. Conclusion paclitaxel and carboplatin intravenous chemotherapy combined with intraperitoneal chemotherapy for advanced ovarian cancer have better curative effect, adverse anti-light and good tolerance.